CureVac NV Final Analysis of Phase 2b/3 Clinical Trial Of CVnCoV - Investor Call Transcript

Jul 01, 2021 / 12:00PM GMT
Sarah Fakih - CureVac N.V. - VP Corporate Communications & IR

Good morning, good afternoon, and welcome to our conference call. My name is Sarah Fakih. I'm the Vice President of Corporate Communications and Investor Relations at CureVac. Please let me introduce today's speakers.

On the call with me are Franz-Werner Haas, the Chief Executive Officer of CureVac; and Ulrike Gnad-Vogt, our Interim Chief Development Officer; Mariola Fotin-Mleczek, CureVac's Chief Technology Officer; and Pierre Kemula, Chief Financial Officer, will be available for the Q&A session after the presentation.

Please note that this call is being webcast live and will be archived on the Events and Presentations section under Investor Relations on our website.

Before we begin, a few forward-looking statements. The discussion and responses to your questions on this call reflect management's views as of today, Thursday, July 1, 2021. We will be making statements and providing responses to your questions that state our intentions, beliefs, expectations or predictions of the future.


Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
4.6 out of 5 Trustpilot